research communications
Seeding for sirtuins: microseed matrix seeding to obtain crystals of human Sirt3 and Sirt2 suitable for soaking
aInstitute of Pharmaceutical Sciences, Albert-Ludwigs-University Freiburg, Albertstrasse 25, 79104 Freiburg, Baden-Württemberg, Germany, and bInstitute of Biochemistry and BIOSS Centre for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Albertstrasse 21, 79104 Freiburg, Baden-Württemberg, Germany
*Correspondence e-mail: einsle@biochemie.uni-freiburg.de, manfred.jung@pharmazie.uni-freiburg.de
Sirtuins constitute a family of NAD+-dependent enzymes that catalyse the cleavage of various from the ∊-amino group of lysines. They regulate a series of cellular processes and their misregulation has been implicated in various diseases, making sirtuins attractive drug targets. To date, only a few sirtuin modulators have been reported that are suitable for cellular research and their development has been hampered by a lack of structural information. In this work, microseed matrix seeding (MMS) was used to obtain crystals of human Sirt3 in its apo form and of human Sirt2 in complex with ADP ribose (ADPR). Crystal formation using MMS was predictable, less error-prone and yielded a higher number of crystals per drop than using conventional crystallization screening methods. The crystals were used to solve the crystal structures of apo Sirt3 and of Sirt2 in complex with ADPR at an improved resolution, as well as the crystal structures of Sirt2 in complex with ADPR and the indoles EX527 and CHIC35. These Sirt2–ADPR–indole complexes unexpectedly contain two indole molecules and provide novel insights into selective Sirt2 inhibition. The MMS approach for Sirt2 and Sirt3 may be used as the basis for structure-based optimization of Sirt2/3 inhibitors in the future.
Keywords: sirtuins; deacylase; deacetylase; seeding; sirtuin–inhibitor complex.
1. Introduction
Sirtuins are a unique NAD+-dependent enzyme family conserved from bacteria to humans that catalyse the cleavage of from the ∊-amino group of lysines (Brachmann et al., 1995). Originally thought to function only as lysine deacetylases, it was recently reported that sirtuins are also able to cleave off other (Feldman et al., 2013). Sirt5 efficiently converts proteins containing succinylated, malonylated and glutarylated lysines, while the isotypes Sirt1, Sirt2, Sirt3 and Sirt6 preferentially cleave off fatty-acid moieties from the ∊-amino group of lysines (Du et al., 2011; Bao et al., 2014; Tan et al., 2014; Liu et al., 2015; Teng et al., 2015). Additionally, several sirtuin isotypes have also been described to be ADP-ribosylases (Du et al., 2009; Pan et al., 2011). However, the physiological roles of post-translational modifications other than acetylation are far from being understood and still need to be further investigated. The initial interest in sirtuins was provoked by reports that sirtuins are critical regulators of aging and that overexpression of specific isotypes may prolong lifespan and impede the onset of age-related diseases by imitating the state of calorie restriction (Howitz et al., 2003; Bordone et al., 2007). However, extensive research has revealed that sirtuins have many other cellular functions (reviewed in Schemies et al., 2010). Thus, they are involved in the regulation of cell-cycle control (Vaquero et al., 2007; Serrano et al., 2013), metabolism (Hirschey et al., 2010), stress response (Bell et al., 2011), autoimmunity (Chuprin et al., 2015) and mitochondrial biogenesis (Milne et al., 2007). Their misregulation has been linked to a variety of pathological processes involved in neurodegenerative diseases (Outeiro et al., 2007) and metabolic disorders (Hirschey et al., 2011). Generally considered as tumour suppressors (Kim et al., 2010, 2011), Sirt1, Sirt2 and Sirt3 have also been shown to assume a role in promoting tumorigenesis in various forms of cancer (Alhazzazi et al., 2011; Liu et al., 2013; Yang et al., 2013). Sirtuins are therefore considered to be potential drug targets. They may also represent targets for antiparasitic drugs (Lancelot et al., 2013). However, cellular studies as well as animal studies have been hampered by the lack of suitable modulators. Of the seven members of the human sirtuin family, Sirt2 is mainly found in the cytoplasm, while Sirt3 is the main mitochondrial deacylase (North et al., 2003; Lombard et al., 2007).
Sirtuins consist of a highly conserved catalytic deacylase domain of around 275 amino acids that is flanked by unstructured N- and C-termini that differ in their length and in their sequence. They have been grouped into four different classes, of which the class I sirtuins Sirt1, Sirt2 and Sirt3 share the highest sequence identity (Fig. 1a). The crystal structures of the deacylase domain of all sirtuin isotypes except Sirt4 and Sirt7 in differently ligated states have been solved to date (Finnin et al., 2001; Jin et al., 2009; Du et al., 2011; Pan et al., 2011; Zhao et al., 2013; Davenport et al., 2014). They show a two-domain structure consisting of a large Rossmann-fold domain and a smaller zinc-binding domain that is typical of sirtuins (Fig. 1b). The two domains are separated by a large cleft that constitutes the catalytic core. Both domains are connected via a series of loops that play important roles during cofactor binding, acyl-lysine binding and the `open-to-closed' rotation. During catalysis, NAD+ adopts a kinked conformation which brings the C1′ of its ribose moiety into proximity for a nucleophilic attack by the carbonyl O atom of the acetyl lysine that is inserted in a hydrophobic tunnel (Fig. 1c). On cleavage of nicotinamide and the formation of an alkylimidate complex, the acetyl group is transferred via several intermediates from the ∊-amino group to the ADP ribose (ADPR) moiety, generating 2′-O-acetyl-ADPR and releasing the deacetylated lysine. Deacylation is thought to proceed in a similar fashion (Feldman et al., 2015). Structural information on sirtuin inhibition is still rather scarce and only recently have several structures of sirtuins in complex with inhibitors been reported (Disch et al., 2013; Gertz et al., 2013; Zhao et al., 2013; Nguyen, Gertz et al., 2013; Nguyen, Schafer et al., 2013; Yamagata et al., 2014; Rumpf et al., 2015). Additional work is still needed to develop rationales for the design of potent and selective modulators that are suitable for cellular studies.
Crystallization of proteins often turns out to be a very demanding objective and initial crystals usually require optimization for diffraction experiments. Seeding is one of the methods that has helped to facilitate the optimization process (Stura & Wilson, 1991; Bergfors, 2003; D'Arcy et al., 2003). It has been shown to enhance the reproducibility of crystal formation and to improve crystal morphology as well as diffraction. Ireton and Stoddard extended the concept of seeding to what they termed microseed matrix seeding (MMS), in which microseeds are transferred to a matrix of diverse buffer conditions (Ireton & Stoddard, 2004). D'Arcy and coworkers incorporated the addition of microseed solutions to screening procedures with standard crystallization robots (D'Arcy et al., 2007). MMS is also widely used in drug-discovery programs. It is usually the best way to obtain large numbers of crystals for high-throughput soaking experiments. Cross-seeding, an approach in which seed crystals of one homologue are used to initiate crystal formation of another one, has also been applied successfully (Obmolova et al., 2010). Current developments in the field of MMS have recently been reviewed and summarized (D'Arcy et al., 2014).
In this work, we describe for the first time the successful application of MMS techniques to human isotypes Sirt2 and Sirt3 from the sirtuin family. We obtained well diffracting crystals of Sirt3 in its apo form and of Sirt2 in complex with the product analogue ADP ribose (ADPR) in diverse crystallization conditions. Using MMS, crystal formation was predictable, less error-prone and yielded a large number of crystals. The crystals were used to obtain crystal structures of Sirt2 in complex with ADPR and of apo Sirt3 at an improved resolution. They also proved to be perfectly suited for the investigation of protein–ligand interactions and were subsequently used to solve two novel crystal structures of Sirt2 in complex with ADPR and indole inhibitors. Both Sirt2–ADPR–indole complexes unexpectedly contained two inhibitor molecules in the active site of Sirt2, highlighting the specific characteristics of Sirt2 within the sirtuin family.
2. Materials and methods
2.1. Cloning, protein expression and protein purification
The gene sequences encoding human Sirt2 (UniProt Q8IXJ6; amino acids 50–356 or 56–356) and human Sirt3 (UniProt Q9NTG7; amino acids 118–395) were cloned in a modified pET-15b vector with a His10 tag instead of a His6 tag and a TEV protease cleavage site instead of a thrombin cleavage site. Human Sirt250–356, Sirt256–356 and Sirt3118–395 were expressed in Escherichia coli strain BL21(DE3) CodonPlus RIPL cells overnight (20°C for Sirt2 and 18°C for Sirt3). Overexpression was induced with IPTG (0.1 mM) at an OD600 of 0.6. The cells were harvested and resuspended in lysis buffer [50 mM Tris–HCl, 500 mM NaCl, 5%(v/v) glycerol, 5 mM β-mercaptoethanol pH 8.0 for Sirt256–356; 50 mM HEPES, 500 mM NaCl, 5%(v/v) glycerol, 5 mM β-mercaptoethanol pH 7.5 for Sirt3 and Sirt250–356]. The cells were then lysed with a microfluidizer (Microfluidics, Westwood, USA) and cell debris was removed via centrifugation. The supernatant was applied onto a HisTrap FF column (5 ml; GE Healthcare, Freiburg, Germany), washed intensively with lysis buffer and then treated with TEV protease (in excess). After overnight digestion (4°C), the digested protein was eluted with lysis buffer, concentrated and further purified with a Superdex S75 26/60 gel-filtration column [GE Healthcare; 25 mM Tris–HCl, 150 mM NaCl pH 8.0 for Sirt256–356; 25 mM HEPES, 200 mM NaCl, 5%(v/v) glycerol, 5 mM β-mercaptoethanol pH 7.5 for Sirt3 and Sirt250–356]. Sirt2- or Sirt3-containing fractions were collected and concentrated to 20 mg ml−1 in the case of Sirt250–356, 13 mg ml−1 in the case of Sirt256–356 and 18.5 mg ml−1 in the case of Sirt3. All purification steps were monitored by SDS–PAGE (Laemmli, 1970) and the protein concentration was determined by the Bradford assay (Bradford, 1976).
2.2. Crystallization and soaking experiments
All crystallization trials were performed in 96-well plates (Intelli-Plate 96-3 Low Profile, Art Robbins Instruments, Sunnyvale, USA) using an OryxNano pipetting robot (Douglas Instruments, Berkshire, England). Index screen was obtained from Hampton Research (Aliso Veijo, USA). The composition of the crystallization solutions in the Index screen can be found at https://hamptonresearch.com/documents/product/hr005585_2-134_formulations.pdf. Crystal formation was monitored with a Minstrel HT UV imaging unit (Rigaku, Kent, England). Initial crystals that were used for MMS of apo Sirt3 (18.5 mg ml−1) were obtained in a solution consisting of 0.2 M Li2SO4, 60%(v/v) Tacsimate (Hampton Research) at pH 7.0 and 4°C with a 1:1 ratio of Sirt3 solution to reservoir solution. Initial crystals of the Sirt256–356–ADPR complex (13 mg ml−1, 20 mM ADPR from a 1 M stock solution in 1 M Tris–HCl buffer pH 9.0) were obtained in a solution consisting of 17.5%(w/v) PEG 10 000, 0.1 M ammonium acetate in 0.1 M bis-tris buffer pH 6.75 at 20°C using a 1:3 ratio of Sirt2–ADPR solution to reservoir solution. Microseed solutions were prepared as follows: 5–10 crystals were harvested, washed, diluted with mother liquor and transferred into an Eppendorf tube, where they were crushed with a seed bead [five cycles of slight vortexing (10 s) followed by incubation on ice (20 s)]. The supernatant was then used for crystallization trials. For crystallization trials using microseed solutions the drop consisted of 17%(v/v) microseed solution, 50–33%(v/v) Sirt3 solution (18.5 mg ml−1) or Sirt2–ADPR solution (13 mg ml−1, 20 mM ADPR) and 33–50%(v/v) reservoir solution. Control experiments to verify that Sirt3 crystal formation was dependent on microseeds were performed with the mother liquor only [60%(v/v) Tacsimate pH 7.0 or 60%(v/v) Tacsimate, 0.2 M Li2SO4 pH 7.0].
Crystals of Sirt250–356 in complex with ADPR [20 mg ml−1, 10 mM NAD+ (Sigma–Aldrich, Deisenhofen, Germany), 100 mM stock solution in 25 mM HEPES, 200 mM NaCl, 5%(v/v) glycerol, 5 mM β-mercaptoethanol pH 7.5] were obtained in a solution consisting of 30%(w/v) PEG 3350, 0.2 M NaCl in 0.1 M bis-tris buffer pH 6.25 at 4°C. The crystals formed after 3–4 d and were mounted on nylon loops before flash-cooling in liquid nitrogen. Apo Sirt3 crystals were obtained by MMS in a solution consisting of 25%(w/v) PEG 3350, 0.2 M MgCl2 in 0.1 M bis-tris buffer pH 5.5 at 4°C. The crystals were cryoprotected by the addition of PEG 3350 to a final concentration of 30%(w/v) PEG 3350, mounted on nylon loops and flash-cooled in liquid nitrogen.
For soaking experiments with indole inhibitors, crystals of Sirt256–356 in complex with ADPR were obtained via MMS in a solution consisting of 18%(w/v) PEG 10 000 in 0.1 M bis-tris buffer pH 5.75 at 20°C. These crystals formed after 1 d and were then soaked in a buffer consisting of 18%(w/v) PEG 10 000, 10%(v/v) DMSO, 0.1 M bis-tris buffer pH 5.75 and either 10 mM EX527 (Sigma–Aldrich, racemic) or 10 mM CHIC35 (Sigma–Aldrich) for 30–90 min. The crystals were cryoprotected by the addition of 20%(v/v) glycerol and were then mounted on nylon loops before flash-cooling in liquid nitrogen.
2.3. Data collection
Data were collected on beamlines X06SA (Sirt250–356–ADPR) and X06DA (apo Sirt3) at the Swiss Light Source, Villigen, Switzerland using Pilatus detectors (Dectris, Baden, Switzerland) at 100 K with oscillations of 0.2 or 0.5° and an X-ray wavelength of 1.0 Å. Data for Sirt256–356 in complex with ADPR and EX243 and data for Sirt256–356 in complex with ADPR and CHIC35 were collected using a MicroMax-007 HF rotating-anode X-ray generator (Rigaku) at a wavelength of 1.5418 Å equipped with a MAR345 image-plate detector (MAR Research, Hamburg, Germany). For each structure, one single crystal was used. Data were processed with MOSFLM (Leslie & Powell, 2007) or XDS (Kabsch, 2010) and scaled using the CC1/2 criterion (Karplus & Diederichs, 2012) with AIMLESS (Evans & Murshudov, 2013) from the CCP4 suite (Winn et al., 2011).
2.4. Structure solution and refinement
All structures were solved by MOLREP (Vagin & Teplyakov, 2010) using a monomer of apo Sirt3 (PDB entry 3gls; Jin et al., 2009) or a monomer of the Sirt2–ADPR complex (PDB entry 3zgv; Moniot et al., 2013) as a search model. Model building was carried out with Coot (Emsley et al., 2010) and the structures were refined with REFMAC5 (Murshudov et al., 2011) or PHENIX (Adams et al., 2010). Crystal as well as the twin fractions were detected using phenix.xtriage from the PHENIX suite (Adams et al., 2010). Twin was achieved with the intensity-based twin-refinement option of REFMAC5. Ligands were generated with the Grade web server (Global Phasing Ltd, Cambridge, England) and were placed into 2Fo − Fc electron-density maps using AFITT-CL (v.2.1.0; OpenEye Scientific Software, Santa Fe, USA). All residues of Sirt2 and Sirt3 except those of the flexible N- and C-termini are defined by electron density. In the crystal structures of the Sirt2–ADPR–indole complexes, a methionine and a histidine are seen at the N-terminus. They originate from the NdeI restriction site of the pET vector. All structures were validated using PROCHECK (Laskowski et al., 1993) and the MolProbity server (Chen et al., 2010). Ramachandran plots for each structure are shown in Supplementary Fig. S3. The data-collection and are summarized in Table 1. The structural sequence alignment was generated with T-Coffee (Di Tommaso et al., 2011) and the images were prepared with PyMOL (v.1.6; Schrödinger). Iterative-build OMIT electron-density maps for the ligands of all structures as well as the hinge loop of the Sirt2–ADPR complex and the surface of the binding pockets were generated with the PHENIX suite (Terwilliger et al., 2008; Adams et al., 2010) and HOLLOW (Ho & Gruswitz, 2008).
with
|
3. Results
3.1. Seeding
Initial crystals of apo Sirt3 were obtained in a solution consisting of 0.2 M lithium sulfate, 60%(v/v) Tacsimate at 4°C (Figs. 2a and 2b). The epitaxically twinned crystals appeared after one week and diffracted to 2.4–3.0 Å resolution. Further optimization of the crystallization conditions did not improve either the crystal morphology or diffraction. Furthermore, initial soaking experiments failed owing to the insolubility of our drug-like ligands in the highly polar Tacsimate condition. We therefore opted for seeding. The use of microseeds in the Index screen (Hampton Research), as described by D'Arcy et al. (2007), proved to be very successful. In the presence of the microseeds, apo Sirt3 crystallized rapidly at different temperatures, in diverse crystallization conditions and in a pH range from 3.5 to 8.5 (Fig. 2c). The best results were obtained with a microseed solution of 1–2 crystals per 10 µl reservoir solution. In most cases, mainly in acidic PEG 3350-containing conditions, apo Sirt3 formed single crystals (Figs. 2d, 2e, 2f and 2g) predictably within several days. They showed an improved diffraction pattern to a resolution of below 2.0 Å. During the initial crystallization screenings we also found that the presence of lithium sulfate was an important nucleation factor, as the initial crystals could only be obtained in the presence of lithium sulfate. We also investigated the influence of lithium sulfate on the crystallization of apo Sirt3 in the presence of microseeds using the Index screen (Hampton Research). Again, apo Sirt3 crystallized rapidly in diverse conditions, over a wide pH range and at different temperatures within days (Supplementary Fig. S1). In a control experiment, we also performed crystallization trials in a similar fashion with the same seeding solutions but without microseeds. Here, we could only observe crystal formation in two different crystallization conditions (data not shown). The formation of the apo Sirt3 crystals was therefore dependent on the presence of microseeds.
3.2. of human apo Sirt3
Diffraction data from a crystal obtained using microseeds were used to solve the structure of the apo form of human Sirt3 by et al. (2009) with PDB code 3gls is 2.7 Å]. Sirt3 crystallized in P21 with six monomers in the All monomers feature the typical sirtuin-like two-domain structure with a larger Rossmann-fold domain and a smaller zinc-binding domain and adopt the `open' conformation. However, they do show some differences within the (r.m.s.d. ranging from 0.2 to 0.8 Å for all Cα atoms of each monomer). A similar behaviour has also been observed in the published of human apo Sirt3 (Jin et al., 2009). Superposition of chain A of the published apo Sirt3 structure (PDB entry 3gls) with chain A of the improved structure of Sirt3 shows a high similarity (r.m.s.d. of 0.25 Å for all Cα atoms). Similar to the published X-ray structure of apo Sirt3, the acyl-lysine binding site of all monomers is occupied by a PEG molecule. This has also been observed in other sirtuin structures (Avalos et al., 2004, 2005).
at a resolution of 1.83 Å [the resolution of the of apo Sirt3 deposited by Jin3.3. Improved of human Sirt2 in complex with ADP ribose
We used two different truncated forms of Sirt2 (Sirt250–356 and Sirt256–356) for crystallization trials of Sirt2. Cross-seeding using microseed solutions of apo Sirt3 failed. However, we succeeded using conventional screening methods and obtained crystals of both Sirt2 forms in complex with ADPR. Initially, Sirt250–356 crystallized in the presence of the cosubstrate NAD+ (2 mM) after a month in Index screen condition F10 (Hampton Research) with a 1:1 ratio of reservoir solution to protein solution at 4°C. This crystallization condition was optimized to 30%(w/v) PEG 3350, 0.2 M NaCl in 0.1 M bis-tris buffer at pH 6.25 and 4°C. Additionally, the NAD+ concentration and the protein:reservoir ratio were increased to 20 mM and 3:1, respectively. Thus, Sirt250–356 crystals appeared within 3–4 d. Using the diffraction data obtained from one of these crystals, we determined the as P212121 and were able to solve the structure of Sirt2 by at a resolution of 1.63 Å (Figs. 3a and 3b; the resolution of the deposited of Sirt2–ADPR was 2.27 Å; PDB entry 3zgv; Moniot et al., 2013). Each Sirt2 molecule contains the product analogue ADPR formed through the hydrolysis of NAD+. The structure of Sirt250–356 in complex with ADPR is very similar to the structure of Sirt2–ADPR recently published by Moniot et al. (2013), but everything is observed in greater detail. The also contains two very similar monomers (r.m.s.d. of 0.19 Å for all Cα atoms) that adopt the `closed' sirtuin conformation. In contrast to the recently published structure, we were also able to include all of the residues of one loop of the hinge region (amino acids 136–144) that connects the Rossmann-fold domain to the zinc-binding domain in our model (Fig. 3c).
However, the handling of the Sirt250–356 crystals turned out to be difficult and the crystals obtained were pseudo-merohedrally twinned. We were also able to obtain crystals with the other truncated form of Sirt256–356 in the presence of ADPR. These crystals formed after just 1 d in an acidic solution of PEG 10 000 at 20°C. They crystallized in the same diffracted equally well, were easier to handle and were not twinned. We also performed MMS with these crystals. As observed for apo Sirt3, the use of microseeds significantly improved the crystallization process in either fine screens or initial screens such as Index screen (Hampton Research; see Figs. 3d, 3e, 3f, 3g and 3h and Supplementary Fig. S2). Again, the crystal count and the predictability of crystal formation were better compared with conventional screening methods set up in the absence of microseeds, while the diffraction quality was equally good.
3.4. Crystal structures of Sirt2 in complex with ADPR and the indole inhibitors EX243 and CHIC35
Owing to the lack of potent Sirt3 modulators, we focused our studies on Sirt2 to validate the suitability of the MMS crystals for soaking experiments. Napper and coworkers published a set of indole inhibitors that show a preference for inhibiting Sirt1 but also block Sirt2 and Sirt3 (Napper et al., 2005; Gertz et al., 2013). Of these indoles, EX527 (selisistat) and CHIC35 are the most potent inhibitors (Fig. 4a). Both have been widely used to study sirtuins in vivo (Solomon et al., 2005; Smith et al., 2014), and EX527 is the first sirtuin inhibitor to date that has been evaluated in clinical trials for the treatment of Huntington's disease (Süssmuth et al., 2015; Westerberg et al., 2015). Furthermore, the indole inhibitors are some of the few inhibitors that have been cocrystallized with human Sirt1, human Sirt3 and the archaeal sirtuin Sir2Tm (Gertz et al., 2013; Zhao et al., 2013). The crystal structures revealed that the more potent S-enantiomer of the indoles is bound to the active site of Sirt1 and Sirt3. The carboxamide of the indole occupies the C-pocket and mimics the physiological inhibitor nicotinamide (Fig. 4b). The chlorinated hydrophobic indole moiety also extends into another binding pocket adjacent to the C-pocket that has been termed the extended C-site (ECS). In addition to the indole, all sirtuin–indole complexes contain either the cofactor NAD+ or the product analogue ADPR. This is in line with kinetic studies, which concluded that the presence of NAD+ or the product analogue ADPR is essential for binding of the indole inhibitor (Napper et al., 2005; Gertz et al., 2013; Zhao et al., 2013). We therefore assumed that the Sirt2–ADPR crystals were perfectly suited for soaking experiments with the indole inhibitors.
Soaking with both indole inhibitors proved to be successful, and DMSO concentrations of up to 10%(v/v) with soaking durations of 90 min did not deteriorate the diffraction pattern of the crystals. Using the diffraction data obtained from the soaked crystals, we were able to solve the crystal structures of Sirt2 in complex with ADPR and either EX243 (EX243 is the S-enantiomer of EX527; Sirt2–ADPR–EX243 structure) or CHIC35 (Sirt2–ADPR–CHIC35 structure) by The of the soaked crystals was determined to be P212121, similar to the of the unsoaked Sirt2–ADPR crystals. The contains two monomers that show no significant differences [r.m.s.d.s of 0.29 Å (Sirt2–ADPR–EX243) and 0.23 Å (Sirt2–ADPR–CHIC35) for all Cα atoms]. The following descriptions are therefore based on chain A. The Sirt2–ADPR–indole complexes adopt the `closed' conformation and share a very close resemblance to the Sirt2–ADPR structure described in §3.3 [r.m.s.d.s of 0.23 Å (Sirt2–ADPR–EX243) and 0.14 Å (Sirt2–ADPR–CHIC35) for all Cα atoms; Fig. 4c]. The only significant differences can be observed at the hinge region (Fig. 4d). Here, the indole inhibitors induce a 6 Å shift of one hinge loop (amino acids 136–144; Fig. 4d). The ADPR molecules of both structures assume a position that is almost identical to that observed in the Sirt2–ADPR complex. To our surprise, each Sirt2 molecule of both Sirt2–ADPR–indole complexes contains two identical indole molecules in an S-configuration (Figs. 4e and 4f). One molecule occupies the C-pocket as well as the extended C-site, and we will refer to this molecule as the `ECS molecule'. The other molecule is found at the hinge region in a pocket that we recently described as the selectivity pocket (Rumpf et al., 2015). We will refer to this molecule as the `hinge molecule'. Both indole molecules of each structure are well defined by electron density; however, the higher B factors of the hinge molecule indicate that the hinge molecule is not present in all Sirt2 molecules or that it is more mobile within the selectivity pocket of Sirt2 (e.g. B factors of 24.1 Å2 for the ECS molecule of Sirt2–ADPR–EX243 and 45.6 Å2 for the hinge molecule of Sirt2–ADPR–EX243). The ECS molecule in both Sirt2–ADPR–indole complexes is involved in a network of hydrophilic and hydrophobic interactions with Sirt2, ADPR and two highly coordinated water molecules (Figs. 5a and 5c). The carboxamide of both indole inhibitors binds in a similar fashion as the carboxamide moiety of the physiological inhibitor nicotinamide and hydrogen-bonds to the highly conserved residues Ile169 and Asp170 and, via one of the water molecules (W24 in Sirt2–ADPR–CHIC35 and W206 in Sirt2–ADPR–EX243), to Ala85, Ile93 and Pro94. The amide of the indole hydrogen-bonds to Gln167 and, via the other highly coordinated water (W3 in Sirt2–ADPR–CHIC35 and W203 in Sirt2–ADPR–EX243), to Asp168 and ADPR. The ECS molecule also interacts with the hydrophobic side chains of Ile93 and Phe96 as well as the hinge molecule. The binding of the hinge molecule is mainly driven by hydrophobic interactions with the side chains of Ala135, Leu138, Tyr139, Phe143 and Phe190. Additionally, the carboxamide moiety of the hinge molecule forms hydrogen bonds to the backbone carbonyl O atoms of Leu138, Tyr139 and Gly141. The interaction pattern of both indole inhibitors in the Sirt2–ADPR–indole complexes is nearly identical. Slight differences can be observed for the conformation of the side chains of Tyr139 and Phe190. Similar interaction patterns for the ECS molecule of both Sirt2–ADPR–indole complexes have also been observed in the crystal structures of Sirt1 and Sirt3 (Gertz et al., 2013; Zhao et al., 2013).
4. Discussion and conclusions
In the presented work, we used an MMS approach to obtain crystals of the potential drug targets human Sirt2 and human Sirt3. With microseeds, we were able to obtain large numbers of crystals predictably in solutions of versatile compositions. Crystal formation was not limited to a specific pH and was not dependent on the presence of a specific crystallization-condition component. As we sought to use these crystals of Sirt2 and Sirt3 for structured-based inhibitor-development studies, the MMS approach provided diverse crystallization conditions to perform soaking experiments. This would not have been possible with such ease using conventional screening approaches. The MMS crystals also diffracted to a higher resolution or equally well in comparison to crystals obtained by conventional screening methods. Using these MMS apo Sirt3 crystals, we were able to solve the X-ray structure of apo Sirt3 at a higher resolution than in the deposited X-ray structure. Additionally, we also provide an improved
of the Sirt2–ADPR complex.To validate the suitability of the Sirt2–ADPR crystals for the investigation of protein–ligand interactions, we also solved the X-ray structures of Sirt2–ADPR in complex with two indole inhibitors termed CHIC35 and EX243. To our surprise, each Sirt2 molecule contained well defined electron density for two indole molecules. One indole mimics the physiological sirtuin inhibitor nicotinamide and occupies the C-pocket and the adjacent extended C-site. Its binding mode is similar to that observed in the crystal structures of the Sirt1–indole and Sirt3–indole complexes. The other inhibitor molecule binds to the selectivity pocket of the hinge region. Such a second indole molecule is not found in the X-ray structures of the Sirt1–NAD+–CHIC35 or the Sirt3–ADPR–EX243 complexes, even though it has to be noted that the authors used slightly lower indole concentrations during crystallization (Gertz et al., 2013; Zhao et al., 2013). The absence of a hinge molecule in the Sirt1–indole and Sirt3–indole complexes is also supported by the fact that the hinge loops of Sirt1 or Sirt3 adopt a similar conformation to that observed in the Sirt2–ADPR complex lacking the indole inhibitors (Fig. 6a). A conformational change of the hinge loop is only seen in the case of the Sirt2–ADPR–indole complexes.
Occupation of the selectivity pocket has also been observed in other crystal structures of Sirt2 by the dimethylpyrimidine moiety (DMP) of the Sirt2-selective inhibitor SirReal2 (Fig. 6b; Rumpf et al., 2015) as well as the long hydrophobic fatty-acid alkyl chain of either thiomyristoylated or myristoylated lysine-containing (Feldman et al., 2015; Teng et al., 2015). Both moieties also extend into the selectivity pocket and partially overlap with the hinge molecule of the Sirt2–ADPR–indole complex (exemplified by the superposition of the Sirt2–ADPR–EX243 complex with the Sirt2–Real2 complex or the Sirt2–thiomyristoylated peptide structure). The hinge molecule, the DMP moiety of SirReal2 or the alkyl chain of the fatty-acid induce diverse conformations of the hinge loop (amino acids 136–144) and enlarge the selectivity pocket significantly (Fig. 6d). Such variable structural changes have not been observed for either Sirt1 or Sirt3 (Supplementary Fig. S7). The hinge molecule may supposedly be of no physiological relevance for Sirt2 inhibition, but it highlights the adaptability of the hinge region of Sirt2 and the selectivity pocket.
In conclusion, this example of MMS underlines the strength of seeding techniques to obtain crystals for structure–activity studies during drug development. Further experiments are still needed to explore the hinge region of sirtuins, to verify the different characteristics within the sirtuin family and to exclude the possibility that the observations are crystallographic artefacts. However, so far a targeting of the selectivity pocket with hydrophobic moieties and exploiting the flexibility of the hinge loop of Sirt2 seems to be a plausible strategy in the search for new Sirt2-selective inhibitors (Fig. 7).
5. Related literature
The following references are cited in the Supporting Information for this article: Clark & Labute (2007) and Szczepankiewicz et al. (2012).
Supporting information
Supporting information. DOI: https://doi.org/10.1107/S2053230X15019986/cb5089sup1.pdf
Acknowledgements
These studies have been supported by Deutsche Forschungsgemeinschaft (Inhibitors, Ju295/8-1; X-ray crystallography, SFB992; Medical Epigenetics, Project Z02). We thank Patrick Shaw Stewart (Douglas Instruments Ltd, England) and Allan D'Arcy (Actelion Pharmaceuticals Ltd, Switzerland) for their valuable feedback on the manuscript.
References
Adams, P. D. et al. (2010). Acta Cryst. D66, 213–221. Web of Science CrossRef CAS IUCr Journals Google Scholar
Alhazzazi, T. Y., Kamarajan, P., Joo, N., Huang, J.-Y., Verdin, E., D'Silva, N. J. & Kapila, Y. L. (2011). Cancer, 117, 1670–1678. CrossRef CAS PubMed Google Scholar
Avalos, J. L., Bever, K. M. & Wolberger, C. (2005). Mol. Cell, 17, 855–868. CrossRef PubMed CAS Google Scholar
Avalos, J. L., Boeke, J. D. & Wolberger, C. (2004). Mol. Cell, 13, 639–648. Web of Science CrossRef PubMed CAS Google Scholar
Bao, X., Wang, Y., Li, X., Li, X.-M., Liu, Z., Yang, T., Wong, C. F., Zhang, J., Hao, Q. & Li, X. D. (2014). Elife, 3, e02999. CrossRef Google Scholar
Bell, E. L., Emerling, B. M., Ricoult, S. J. H. & Guarente, L. (2011). Oncogene, 30, 2986–2996. CrossRef CAS PubMed Google Scholar
Bergfors, T. (2003). J. Struct. Biol. 142, 66–76. Web of Science CrossRef PubMed CAS Google Scholar
Bordone, L., Cohen, D., Robinson, A., Motta, M. C., Van Veen, E., Czopik, A., Steele, A. D., Crowe, H., Marmor, S., Luo, J., Gu, W. & Guarente, L. (2007). Aging Cell, 6, 759–767. CrossRef PubMed CAS Google Scholar
Brachmann, C. B., Sherman, J. M., Devine, S. E., Cameron, E. E., Pillus, L. & Boeke, J. D. (1995). Genes Dev. 9, 2888–2902. CrossRef CAS PubMed Google Scholar
Bradford, M. M. (1976). Anal. Biochem. 72, 248–254. Web of Science CrossRef CAS PubMed Google Scholar
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson, D. C. (2010). Acta Cryst. D66, 12–21. Web of Science CrossRef CAS IUCr Journals Google Scholar
Chuprin, A. et al. (2015). Nature Immunol. 16, 737–745. CrossRef CAS Google Scholar
Clark, A. M. & Labute, P. (2007). J. Chem. Inf. Model. 47, 1933–1944. Web of Science CrossRef PubMed CAS Google Scholar
D'Arcy, A., Bergfors, T., Cowan-Jacob, S. W. & Marsh, M. (2014). Acta Cryst. F70, 1117–1126. Web of Science CrossRef IUCr Journals Google Scholar
D'Arcy, A., Mac Sweeney, A. & Haber, A. (2003). Acta Cryst. D59, 1343–1346. Web of Science CrossRef CAS IUCr Journals Google Scholar
D'Arcy, A., Villard, F. & Marsh, M. (2007). Acta Cryst. D63, 550–554. Web of Science CrossRef CAS IUCr Journals Google Scholar
Davenport, A. M., Huber, F. M. & Hoelz, A. (2014). J. Mol. Biol. 426, 526–541. CrossRef CAS PubMed Google Scholar
Disch, J. S. et al. (2013). J. Med. Chem. 56, 3666–3679. Web of Science CrossRef CAS PubMed Google Scholar
Di Tommaso, P., Moretti, S., Xenarios, I., Orobitg, M., Montanyola, A., Chang, J.-M., Taly, J.-F. & Notredame, C. (2011). Nucleic Acids Res. 39, W13–W17. Web of Science CrossRef CAS PubMed Google Scholar
Du, J., Jiang, H. & Lin, H. (2009). Biochemistry, 48, 2878–2890. CrossRef PubMed CAS Google Scholar
Du, J. et al. (2011). Science, 334, 806–809. Web of Science CrossRef CAS PubMed Google Scholar
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486–501. Web of Science CrossRef CAS IUCr Journals Google Scholar
Evans, P. R. & Murshudov, G. N. (2013). Acta Cryst. D69, 1204–1214. Web of Science CrossRef CAS IUCr Journals Google Scholar
Feldman, J. L., Baeza, J. & Denu, J. M. (2013). J. Biol. Chem. 288, 31350–31356. CrossRef CAS PubMed Google Scholar
Feldman, J. L., Dittenhafer-Reed, K. E., Kudo, N., Thelen, J. N., Ito, A., Yoshida, M. & Denu, J. M. (2015). Biochemistry, 54, 3037–3050. CrossRef CAS PubMed Google Scholar
Finnin, M. S., Donigian, J. R. & Pavletich, N. P. (2001). Nature Struct. Biol. 8, 621–625. Web of Science CrossRef PubMed CAS Google Scholar
Gertz, M., Fischer, F., Nguyen, G. T. T., Lakshminarasimhan, M., Schutkowski, M., Weyand, M. & Steegborn, C. (2013). Proc. Natl Acad. Sci. USA, 110, E2772–E2781. CrossRef CAS PubMed Google Scholar
Hirschey, M. D. et al. (2010). Nature (London), 464, 121–125. CrossRef CAS PubMed Google Scholar
Hirschey, M. D. et al. (2011). Mol. Cell, 44, 177–190. Web of Science CrossRef CAS PubMed Google Scholar
Ho, B. K. & Gruswitz, F. (2008). BMC Struct. Biol. 8, 49. Google Scholar
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., Scherer, B. & Sinclair, D. A. (2003). Nature (London), 425, 191–196. Web of Science CrossRef PubMed CAS Google Scholar
Ireton, G. C. & Stoddard, B. L. (2004). Acta Cryst. D60, 601–605. Web of Science CrossRef CAS IUCr Journals Google Scholar
Jin, L., Wei, W., Jiang, Y., Peng, H., Cai, J., Mao, C., Dai, H., Choy, W., Bemis, J. E., Jirousek, M. R., Milne, J. C., Westphal, C. H. & Perni, R. B. (2009). J. Biol. Chem. 284, 24394–24405. Web of Science CrossRef PubMed CAS Google Scholar
Kabsch, W. (2010). Acta Cryst. D66, 125–132. Web of Science CrossRef CAS IUCr Journals Google Scholar
Karplus, P. A. & Diederichs, K. (2012). Science, 336, 1030–1033. Web of Science CrossRef CAS PubMed Google Scholar
Kim, H.-S. et al. (2010). Cancer Cell, 17, 41–52. CrossRef CAS PubMed Google Scholar
Kim, H.-S. et al. (2011). Cancer Cell, 20, 487–499. CrossRef CAS PubMed Google Scholar
Laemmli, U. K. (1970). Nature (London), 227, 680–685. CrossRef CAS PubMed Web of Science Google Scholar
Lancelot, J., Caby, S., Dubois-Abdesselem, F., Vanderstraete, M., Trolet, J., Oliveira, G., Bracher, F., Jung, M. & Pierce, R. J. (2013). PLoS Negl. Trop. Dis. 7, e2428. CrossRef PubMed Google Scholar
Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M. (1993). J. Appl. Cryst. 26, 283–291. CrossRef CAS Web of Science IUCr Journals Google Scholar
Leslie, A. G. W. & Powell, H. R. (2007). Evolving Methods for Macromolecular Crystallography, edited by R. J. Read & J. L. Sussman, pp. 41–51. Dordrecht: Springer. Google Scholar
Liu, P. Y. et al. (2013). Cell Death Differ. 20, 503–514. CrossRef CAS PubMed Google Scholar
Liu, Z., Yang, T., Li, X., Peng, T., Hang, H. C. & Li, X. D. (2015). Angew. Chem. Int. Ed. 54, 1149–1152. CrossRef CAS Google Scholar
Lombard, D. B. et al. (2007). Mol. Cell. Biol. 27, 8807–8814. CrossRef PubMed CAS Google Scholar
Milne, J. C. et al. (2007). Nature (London), 450, 712–716. Web of Science CrossRef PubMed CAS Google Scholar
Moniot, S., Schutkowski, M. & Steegborn, C. (2013). J. Struct. Biol. 182, 136–143. Web of Science CrossRef CAS PubMed Google Scholar
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). Acta Cryst. D67, 355–367. Web of Science CrossRef CAS IUCr Journals Google Scholar
Napper, A. D. et al. (2005). J. Med. Chem. 48, 8045–8054. CSD CrossRef PubMed CAS Google Scholar
Nguyen, G. T. T., Gertz, M. & Steegborn, C. (2013). Chem. Biol. 20, 1375–1385. CrossRef CAS PubMed Google Scholar
Nguyen, G. T. T., Schaefer, S., Gertz, M., Weyand, M. & Steegborn, C. (2013). Acta Cryst. D69, 1423–1432. CrossRef IUCr Journals Google Scholar
North, B. J., Marshall, B. L., Borra, M. T., Denu, J. M. & Verdin, E. (2003). Mol. Cell, 11, 437–444. Web of Science CrossRef PubMed CAS Google Scholar
Obmolova, G., Malia, T. J., Teplyakov, A., Sweet, R. & Gilliland, G. L. (2010). Acta Cryst. D66, 927–933. Web of Science CrossRef CAS IUCr Journals Google Scholar
Outeiro, T. F., Kontopoulos, E., Altmann, S. M., Kufareva, I., Strathearn, K. E., Amore, A. M., Volk, C. B., Maxwell, M. M., Rochet, J.-C., McLean, P. J., Young, A. B., Abagyan, R., Feany, M. B., Hyman, B. T. & Kazantsev, A. G. (2007). Science, 317, 516–519. CrossRef PubMed CAS Google Scholar
Pan, P. W., Feldman, J. L., Devries, M. K., Dong, A., Edwards, A. M. & Denu, J. M. (2011). J. Biol. Chem. 286, 14575–14587. CrossRef CAS PubMed Google Scholar
Rumpf, T. et al. (2015). Nature Commun. 6, 6263. CrossRef Google Scholar
Schemies, J., Uciechowska, U., Sippl, W. & Jung, M. (2010). Med. Res. Rev. 30, 861–889. CrossRef PubMed CAS Google Scholar
Serrano, L., Martínez-Redondo, P., Marazuela-Duque, A., Vazquez, B. N., Dooley, S. J., Voigt, P., Beck, D. B., Kane-Goldsmith, N., Tong, Q., Rabanal, R. M., Fondevila, D., Muñoz, P., Krüger, M., Tischfield, J. A. & Vaquero, A. (2013). Genes Dev. 27, 639–653. CrossRef CAS PubMed Google Scholar
Smith, M. R. et al. (2014). Hum. Mol. Genet. 23, 2995–3007. CrossRef CAS PubMed Google Scholar
Solomon, J. M., Pasupuleti, R., Xu, L., McDonagh, T., Curtis, R., DiStefano, P. S. & Huber, L. J. (2005). Mol. Cell. Biol. 26, 28–38. CrossRef Google Scholar
Stura, E. A. & Wilson, I. A. (1991). J. Cryst. Growth, 110, 270–282. CrossRef CAS Web of Science Google Scholar
Süssmuth, S. D. et al. (2015). Br. J. Clin. Pharmacol. 79, 465–476. PubMed Google Scholar
Szczepankiewicz, B. G., Dai, H., Koppetsch, K. J., Qian, D., Jiang, F., Mao, C. & Perni, R. B. (2012). J. Org. Chem. 77, 7319–7329. Web of Science CrossRef CAS PubMed Google Scholar
Tan, M. et al. (2014). Cell Metab. 19, 605–617. CrossRef CAS PubMed Google Scholar
Teng, Y.-B., Jing, H., Aramsangtienchai, P., He, B., Khan, S., Hu, J., Lin, H. & Hao, Q. (2015). Sci. Rep. 5, 8529. CrossRef PubMed Google Scholar
Terwilliger, T. C., Grosse-Kunstleve, R. W., Afonine, P. V., Moriarty, N. W., Adams, P. D., Read, R. J., Zwart, P. H. & Hung, L.-W. (2008). Acta Cryst. D64, 515–524. Web of Science CrossRef CAS IUCr Journals Google Scholar
Vagin, A. & Teplyakov, A. (2010). Acta Cryst. D66, 22–25. Web of Science CrossRef CAS IUCr Journals Google Scholar
Vaquero, A., Sternglanz, R. & Reinberg, D. (2007). Oncogene, 26, 5505–5520. CrossRef PubMed CAS Google Scholar
Westerberg, G., Chiesa, J. A., Andersen, C. A., Diamanti, D., Magnoni, L., Pollio, G., Darpo, B. & Zhou, M. (2015). Br. J. Clin. Pharmacol. 79, 477–491. CrossRef CAS PubMed Google Scholar
Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242. Web of Science CrossRef CAS IUCr Journals Google Scholar
Yamagata, K., Goto, Y., Nishimasu, H., Morimoto, J., Ishitani, R., Dohmae, N., Takeda, N., Nagai, R., Komuro, I., Suga, H. & Nureki, O. (2014). Structure, 22, 345–352. CrossRef CAS PubMed Google Scholar
Yang, M. H., Laurent, G., Bause, A. S., Spang, R., German, N., Haigis, M. C. & Haigis, K. M. (2013). Mol. Cancer Res. 11, 1072–1077. CrossRef CAS PubMed Google Scholar
Zhao, X., Allison, D., Condon, B., Zhang, F., Gheyi, T., Zhang, A., Ashok, S., Russell, M., MacEwan, I., Qian, Y., Jamison, J. A. & Luz, J. G. (2013). J. Med. Chem. 56, 963–969. Web of Science CrossRef CAS PubMed Google Scholar
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.